Abstract
Original language | English |
---|---|
Journal | Alzheimer s & dementia |
Early online date | 17 Jun 2022 |
DOIs | |
Publication status | E-pub ahead of print - 17 Jun 2022 |
Keywords
- Alzheimer's
- PET
- amyloid
- dementia
- memory clinic population
- mild cognitive impairment
- subjective cognitive decline
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Alzheimer s & dementia, 17.06.2022.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Description of a European memory clinic cohort undergoing amyloid-PET
T2 - The AMYPAD Diagnostic and Patient Management Study
AU - Altomare, Daniele
AU - Collij, Lyduine
AU - Caprioglio, Camilla
AU - Scheltens, Philip
AU - van Berckel, Bart N. M.
AU - Alves, Isadora Lopes
AU - Berkhof, Johannes
AU - de Gier, Yvonne
AU - Garibotto, Valentina
AU - Moro, Christian
AU - Poitrine, L. a
AU - Delrieu, Julien
AU - Payoux, Pierre
AU - Saint-Aubert, Laure
AU - Molinuevo, José Luis
AU - Grau-Rivera, Oriol
AU - Gispert, Juan-Domingo
AU - Minguillón, Carolina
AU - Fauria, Karine
AU - Sanchez, Marta Felez
AU - Rădoi, Andreea
AU - Drzezga, Alexander
AU - Jessen, Frank
AU - Escher, Claus
AU - Zeyen, Philip
AU - Nordberg, Agneta
AU - Savitcheva, Irina
AU - Jelic, Vesna
AU - Walker, Zuzana
AU - Lee, Ho-Yun
AU - Lee, Lean
AU - Demonet, Jean-François
AU - Plaza Wuthrich, Sonia
AU - Gismondi, Rossella
AU - Farrar, Gill
AU - the AMYPAD Consortium
AU - Barkhof, Frederik
AU - Stephens, Andrew W.
AU - Frisoni, Giovanni B.
N1 - Funding Information: Philip Scheltens provides consultancy (via the University) for AC Immune, Alzheon, Brainstorm Cell, ImmunoBrain Checkpoint, Novartis, and Novo Nordisk. Within his university affiliation he is principal investigator of studies with AC Immune, FUJI‐film/Toyama, IONIS, UCB, and Vivoryon. He is also an employee of Life Sciences Partners Amsterdam. Valentina Garibotto received financial support for research and/or speaker fees through her institution from Siemens Healthineers, GE Healthcare, Life Molecular Imaging, Cerveau Technologies, Roche, and Merck. Julien Delrieu has received payment/honoraria from Biogen (presentation for Biogen in 2021); and has participated on a Data Safety Monitoring Board or Advisory Board for French board for Roche in 2020–2021. José Luis Molinuevo is currently a full‐time employee of Lundbeck and has served previously as a consultant or on advisory boards for the following for‐profit companies, or has given lectures in symposia sponsored by the following for‐profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, and ProMIS Neurosciences. Juan Domingo Gispert received research support from GE Healthcare, Hoffmann La Roche, and Roche Diagnostics; and speaker's fees from Philips and Biogen. Alexander Drzezga received research support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, and SOFIE. Speaker Honorary/Advisory Boards: by Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk, and Invicro. Stock from: Siemens Healthineers, Lantheus Holding, and Biogen. Patents: Patent pending for 18F‐PSMA7 (PSMA PET imaging tracer). He provided expert testimony in a local court. He has participated on a Data Safety Monitoring Board or Advisory Board for GE Healthcare, Siemens Healthineers, Novo Nordisk, Invicro, and Biogen. Frank Jessen received payment/honoraria from Roche and Lilly. He has participated on a Data Safety Monitoring Board or Advisory Board for AC Immune, Biogen, Roche, Eisai, and Grifols. Agneta Nordberg received consulting fees from Hoffman La Roche. Patent: US patent alpha 7 nicotinic PET tracer. She is deputy chairman of Wennergren Foundations. Zuzana Walker received consulting fees from GE Healthcare. Jean‐François Demonet: patent (European Patent Office 19705763.1‐1132). He has participated on an Advisory Board for Biogen Switzerland. Frederik Barkhof received consulting fees from Combinostics, IXICO, Roche, and Biogen. He has participated on a Data Safety Monitoring Board or Advisory Board for EISAI, Biogen, and Merck. Giovanni B. Frisoni reports grants from Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, IXICO, Merz Pharma, Nestlé, Novartis, Eisai, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, and Vifor Pharma; he has received personal fees from AstraZeneca, Avid Radiopharmaceuticals, Biogen, Roche, Diadem, Neurodiem, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics. The other authors have nothing to disclose. Funding Information: This communication reflects the views of the authors and neither the Innovative Medicines Initiative (IMI) nor the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are liable for any use that may be made of the information contained herein. The Geneva Memory Center is funded by the following private donors under the supervision of the Private Foundation of Geneva University Hospitals: A.P.R.A. ‐ Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève. Competitive research projects have been funded by: H2020, Human Brain Project, Innovative Medicines Initiative (IMI), IMI2, Swiss National Science Foundation, VELUX Foundation. External sites affiliated with CHUT: Françoise Desclaux (Geriatrics department of Lavaur), Marie‐Noelle Cufi (Geriatrics department of Lavaur), and Jérémie Pariente (department of Neurology of Toulouse University Hospital, Inserm Toulouse NeuroImaging Center, Université Paul Sabatier, Centre d'Investigation Clinique de Toulouse CIC 1436). The BBRC's memory center received funding from the Barcelona City Council (agreement # 20XC0354) and Biogen. Daniele Altomare received funding from the Fondation Recherche Alzheimer and the Swiss National Science Foundation (project CRSK‐3_196354/1). Camilla Caprioglio was supported by EU‐EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Johannes Berkhof is a recipient of ABOARD, which is a public‐private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106), and received funding from the EU (AMYPAD, RISCC), ZonMW (HPV compare), WHO, IARC, and RIVM. Valentina Garibotto was supported by the Swiss National Science Foundation (projects 320030_169876, 320030_185028 and IZSEZ0_188355), by the Velux Foundation (project 1123), by the Schmidheiny foundation, and by the Aetas foundation. Oriol Grau‐Rivera received funding from Alzheimer's Association (2019‐AARF‐644568) and Instituto de Salud Carlos III (PI19/00117). Juan Domingo Gispert is supported by the Spanish Ministry of Science and Innovation (RYC‐2013‐13054) and received funding from the EU‐EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Alexander Drzezga received funding by Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952), DFG (Deutsche Forschungsgemeinschaft), BMBF (Bundesministerium für Bildung und Forschung), EFRE/Leitmarkt (Europäischen Fonds für regionale Entwicklung), University of Cologne, Forschungszentrum Jülich. Novartis clinical trial. Claus Escher received funding from the EU‐EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) European Prevention of Alzheimer's Dementia consortium (EPAD, grant agreement number: 115736) and Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Frank Jessen received funding from BMBF, DFG, H2020, and IMI. Agneta Nordberg received funding from Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952), Swedish Foundation for Strategic Research (RB12‐01929), Swedish Research Council (2017‐06086, 2017‐02965, 2020‐019909, CIMED, Swedish Brain Foundation, Swedish Alzheimer foundation, Recherche Sur Alzheimer Fondation, France, and Michael J Fox Foundation (MJFF‐019728). Zuzana Walker received funding from HTA‐NIHR, Lewy body Society, and ARUK. Jean‐François Demonet received funding from Biogen “EMBARK” study, Empiris foundation, Solis foundation, OM Pharma, and Leenaards foundation. Frederik Barkhof is supported by the NIHR Biomedical Research Centre at University College London Hospitals. Giovanni B. Frisoni received funding from the EU‐EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) European Prevention of Alzheimer's Dementia consortium (EPAD, grant agreement number: 115736) and Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952); the Swiss National Science Foundation (COSCODE, grant number: 320030_182772); A.P.R.A. ‐ Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève; and VELUX Foundation. Publisher Copyright: © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2022/6/17
Y1 - 2022/6/17
N2 - Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants’ baseline features and discuss the representativeness of the cohort. Methods: Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice. Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms. Discussion: The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.
AB - Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants’ baseline features and discuss the representativeness of the cohort. Methods: Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice. Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms. Discussion: The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.
KW - Alzheimer's
KW - PET
KW - amyloid
KW - dementia
KW - memory clinic population
KW - mild cognitive impairment
KW - subjective cognitive decline
UR - http://www.scopus.com/inward/record.url?scp=85133684837&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/alz.12696
DO - https://doi.org/10.1002/alz.12696
M3 - Article
C2 - 35715930
SN - 1552-5260
JO - Alzheimer s & dementia
JF - Alzheimer s & dementia
ER -